PHARMANORD
COQ10: IDENTIFYING A SUB-STANDARD SUPPLEMENT
RECENT STUDIES HAVE SHOWN THAT COQ10 CAN HELP REDUCE THE RISK OF MORTALITY IN PATIENTS WITH HEART FAILURE BY AROUND 50% AND YET SOME OF YOUR CUSTOMERS COULD BE BUYING FRAUDULENT OR SUBSTANDARD PRODUCTS.
of concerns about counterfeiting of their product. The quality of a supplement is key to its efficacy and Pharmacists can play a key role in educating customers on how to identify a quality product.
R Q10 AND HEART HEALTH
CoQ10 is a naturally occurring vitamin-like substance that plays a key role in supplying the body with its energy requirements. CoQ10 is required by the body for the normal functioning of all tissues and those with the highest energy requirements (heart and muscles) are particularly reliant on an adequate supply, it is also important as a cell membrane protecting antioxidant. Again this is of particular importance in heart tissue, where cardiac cells are exposed to high levels of potentially damaging free radicals. The heart is especially dependent on maintaining adequate tissue levels of Q10 for normal functioning and patients with heart disorders such as heart failure
14 - PHARMACY IN FOCUS
ecently, a major raw material supplier of CoQ10 carried out a re-branding exercise because
invariably have insufficient levels of Q10.
A small amount of CoQ10 is obtained from a normal diet, with most of the daily requirement produced within the body. As people age, the body’s capacity to produce its own CoQ10 is reduced; CoQ10 levels are also depleted by intense exercise, statin use or chronic disease hence the rationale for CoQ10 supplementation.
SUPPORTED BY RESEARCH
Bio-Quinone Q10 was selected by the Danish cardiologist and researcher, Chief Physician Svend Aage Mortensen, from the Copenhagen Heart Centre, in his role as the lead researcher behind the ground breaking international trial called Q-Symbio, which was published in the esteemed Journal of the American College of Cardiology, HEART FAILURE.
A total of 420 patients with chronic heart failure participated in the study, with each patient undergoing a total of two years of treatment. Half of the patients were assigned to three daily
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64